Agilent Technologies Inc. (A) and Laboratory Corporation of America Holdings (NYSE:LH) Comparison side by side

Both Agilent Technologies Inc. (NYSE:A) and Laboratory Corporation of America Holdings (NYSE:LH) are Medical Laboratories & Research companies, competing one another. We will contrast their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agilent Technologies Inc. 74 4.28 N/A 3.53 19.69
Laboratory Corporation of America Holdings 162 1.42 N/A 9.09 18.43

Table 1 shows top-line revenue, earnings per share and valuation of the two companies. Laboratory Corporation of America Holdings seems to has higher revenue and earnings compared to Agilent Technologies Inc. The business that is more expensive between the two has a higher price-to-earnings ratio. Agilent Technologies Inc. is trading at a higher price-to-earnings ratio than Laboratory Corporation of America Holdings, indicating that it is presently more expensive of the two stocks.


Table 2 demonstrates the return on assets, net margins and return on equity of Agilent Technologies Inc. and Laboratory Corporation of America Holdings.

Net Margins Return on Equity Return on Assets
Agilent Technologies Inc. 0.00% 23.2% 12.8%
Laboratory Corporation of America Holdings 0.00% 12.5% 5.3%

Risk and Volatility

A 1.41 beta indicates that Agilent Technologies Inc. is 41.00% more volatile compared to S&P 500. Laboratory Corporation of America Holdings’s 5.00% more volatile than S&P 500 which is a result of the 1.05 beta.


Agilent Technologies Inc.’s Current Ratio is 3.4 while its Quick Ratio is 2.8. On the competitive side is, Laboratory Corporation of America Holdings which has a 1.1 Current Ratio and a 1 Quick Ratio. Agilent Technologies Inc. is better positioned to pay off short and long-term obligations compared to Laboratory Corporation of America Holdings.

Analyst Recommendations

Ratings and Recommendations for Agilent Technologies Inc. and Laboratory Corporation of America Holdings can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Agilent Technologies Inc. 0 0 2 3.00
Laboratory Corporation of America Holdings 0 2 5 2.71

The average price target of Agilent Technologies Inc. is $89.33, with potential upside of 25.62%. Competitively Laboratory Corporation of America Holdings has a consensus price target of $188.86, with potential upside of 12.71%. Based on the analysts view we can conclude, Agilent Technologies Inc. is looking more favorable than Laboratory Corporation of America Holdings.

Institutional and Insider Ownership

Roughly 89.8% of Agilent Technologies Inc. shares are owned by institutional investors while 95.4% of Laboratory Corporation of America Holdings are owned by institutional investors. Insiders owned roughly 0.4% of Agilent Technologies Inc.’s shares. Competitively, Laboratory Corporation of America Holdings has 0.5% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Agilent Technologies Inc. -0.24% -8.41% -10.4% -7.99% 7.4% 2.89%
Laboratory Corporation of America Holdings -5.94% -4.29% 3.95% 21.07% -2.94% 32.57%

For the past year Agilent Technologies Inc. has weaker performance than Laboratory Corporation of America Holdings


Agilent Technologies Inc. beats on 8 of the 12 factors Laboratory Corporation of America Holdings.

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. Its Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The companyÂ’s Diagnostics and Genomics segment provides reagents, instruments, software, and consumables; arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment services; and equipment focused on production of synthesized oligonucleotides for use as active pharmaceutical ingredients. Its Agilent CrossLab segment offers GC and LC columns, sample preparation products, custom chemistries, and various laboratory instrument supplies; and startup, operational, training, and compliance support, as well as asset management and consultation services. The company markets and sells its products through direct sales, electronic commerce, resellers, manufacturers' representatives, and distributors. It has a collaboration agreement with University of Leuven to focus on detecting genetic abnormalities in cell-free DNA and embryo biopsies. Agilent Technologies, Inc. was founded in 1999 and is headquartered in Santa Clara, California.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. The company offers a range of clinical laboratory tests and procedures, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, PSA, tests for sexually-transmitted diseases, HCV tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. It also provides specialty testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, the company provides drug development solutions, as well as laboratory testing services. Further, it provides its testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Duke University, Johns Hopkins University, Boston University, Columbia University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests. Laboratory Corporation of America Holdings was founded in 1971 and is headquartered in Burlington, North Carolina.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.